Global methylation profiling for risk prediction of prostate cancer

Clinical Cancer Research

Volumn 18, Issue 10, 2012, Pages 2882-2895

  Mahapatra, Saswati ^a   Klee, Eric W ^a   Young, Charles Y F ^a   Sun, Zhifu ^a   Jimenez, Rafael E ^a   Klee, George G ^a   Tindall, Donald J ^a   Donkena, Krishna Vanaja ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADULT; ARTICLE; BCL11B GENE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; CRIP1 GENE; DNA METHYLATION; EARLY DIAGNOSIS; FLNC GENE; GENE IDENTIFICATION; GENETIC ANALYSIS; GSTP1 GENE; HAAO GENE; HIF3A GENE; HS3ST2 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PHLDA3 GENE; POU3F3 GENE; PRIORITY JOURNAL; PROSTATE CANCER; PYROSEQUENCING; RAR BETA GENE; RASGRF2 GENE; RECURRENCE RISK; RISK ASSESSMENT; RUNX3 GENE; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TNFRSF10D GENE; TUMOR GENE;

DNA METHYLATION; DNA, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861153520     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2090     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Damber JE, Aus G. Prostate cancer. Lancet 2008;371:1710-21. (Pubitemid 351671887)
3. Sciarra A, Cattarino S, Gentilucci A, Salciccia S, Alfarone A, Mariotti G, et al. Update on screening in prostate cancer based on recent clinical trials. Rev Recent Clin Trials 2011;6:7-15.
4. Tenke P, Horti J, Balint P, Kovacs B. Prostate cancer screening. Recent Results Cancer Res 2007;175:65-81.
5. Karnes RJ, Cheville JC, Ida CM, Sebo TJ, Nair AA, Tang H, et al. The ability of biomarkers to predict systemic progression in men with highrisk prostate cancer treated surgically is dependent on ERG status. Cancer Res 2010;70:8994-9002.
6. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, Fearn PA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715-7. (Pubitemid 43821789)
7. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165:119-25.
8. Briganti A, Gallina A, Suardi N, Chun FK, Walz J, Heuer R, et al. A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer. BJU Int 2008;101: 556-60. (Pubitemid 351199277) (Pubitemid 351199277)
9. Madu CO, Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer 2010;1:150-77.
10. Brait M, Sidransky D. Cancer epigenetics: above and beyond. Toxicol Mech Methods 2011;21:275-88.
11. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011;17:330-9.
12. Kulis M, Esteller M. DNA methylation and cancer. Adv Genet 2010;70: 27-56.
13. Watanabe Y, Maekawa M. Methylation of DNA in cancer. Adv Clin Chem 2010;52:145-67.
14. Park JY. Promoter hypermethylation in prostate cancer. Cancer Control 2010;17:245-55.
15. Richiardi L, Fiano V, Vizzini L, De Marco L, Delsedime L, Akre O, et al. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 2009;27:3161-8.
16. Vanaja DK, Ballman KV, Morlan BW, Cheville JC, Neumann RM, Lieber MM, et al. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res 2006;12:1128-36. (Pubitemid 43342500) (Pubitemid 43342500)
17. Vanaja DK, Grossmann ME, Cheville JC, Gazi MH, Gong A, Zhang JS, et al. PDLIM4, an actin binding protein, suppresses prostate cancer cell growth. Cancer Invest 2009;27:264-72.
18. Woodson K, Hayes R, Wideroff L, Villaruz L, Tangrea J. Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate 2003;55:199-205. (Pubitemid 36532399)
19. Maliukova AV, Loginov VI, Khodyrev DS, Kadyrova EL, Pronina IV, Ivanova TA, et al. Methylation of the putative tumor suppressor gene, RASSF1A, in primary cervical tumors.Mol Biol (Mosk) 2004;38:1005-13. (Pubitemid 44558337) (Pubitemid 44558337)
20. Li LC, Okino ST, Dahiya R. DNA methylation in prostate cancer. Biochim Biophys Acta 2004;1704:87-102.
21. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, et al. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest 2009;27:549-60.
22. Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003;63:3877-82. (Pubitemid 36917897) (Pubitemid 36917897)
23. Chowdhury S, Erickson SW, MacLeod SL, Cleves MA,Hu P, Karim MA, et al. Maternal genome-wideDNA methylation patterns and congenital heart defects. PLoS One 2011;6:e16506.
24. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5. (Pubitemid 37033947) (Pubitemid 37033947)
25. White HE, Durston VJ, Harvey JF, Cross NC. Quantitative analysis of SNRPN(correction of SRNPN) gene methylation by pyrosequencing as a diagnostic test for Prader-Willi syndrome and Angelman syndrome. Clin Chem 2006;52:1005-13. (Pubitemid 43794410) (Pubitemid 43794410)
26. Sun Z, Chai HS, Wu Y, White WM, Donkena KV, Klein CJ, et al. Batch effect correction for genome-wide methylation data with Illumina Infinium platform. BMC Med Genomics 2011;4:84.
27. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005;97: 103-15. (Pubitemid 40277090) (Pubitemid 40277090)
28. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-86. (Pubitemid 38339443) (Pubitemid 38339443)
29. Donkena KV, Young CY, Tindall DJ. Oxidative stress and DNA methylation in prostate cancer. Obstet Gynecol Int 2010;2010:302051.
30. Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, et al. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res 2007;13:5361-7. (Pubitemid 47510361) (Pubitemid 47510361)
31. Woodson K, O'Reilly KJ, Ward DE, Walter J, Hanson J, Walk EL, et al. CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics 2006;1:183-6.
32. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005;11:8321-5. (Pubitemid 41746943) (Pubitemid 41746943)
33. Pasanen A, Heikkila M, Rautavuoma K, Hirsila M, Kivirikko KI, Myllyharju J. Hypoxia-inducible factor (HIF)-3alpha is subject to extensive alternative splicing in human tissues and cancer cells and is regulated by HIF-1 but not HIF-2. Int J Biochem Cell Biol 2010;42: 1189-200.
34. Huang YW, Luo J, Weng YI, Mutch DG, Goodfellow PJ, Miller DS, et al. Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. Gynecol Oncol 2010;117:239-47.
35. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858-87. (Pubitemid 40461690) (Pubitemid 40461690)
36. Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G, IttmannM, et al. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 2009;181: 1678-85.
37. Ito K. RUNX3 in oncogenic and anti-oncogenic signaling in gastrointestinal cancers. J Cell Biochem 2011;112:1243-9.
38. Shworak NW, Liu J, Fritze LM, Schwartz JJ, Zhang L, Logeart D, et al. Molecular cloning and expression of mouse and human cDNAs encoding heparan sulfate D-glucosaminyl 3-O-sulfotransferase. J Biol Chem 1997;272:28008-19. (Pubitemid 27473608) (Pubitemid 27473608)
39. Hempe JM, Cousins RJ. Cysteine-rich intestinal protein binds zinc during transmucosal zinc transport. Proc Natl Acad Sci U S A 1991;88:9671-4. (Pubitemid 21915693) (Pubitemid 21915693)
40. Ruiz S, Santos E, Bustelo XR. RasGRF2, a guanosine nucleotide exchange factor for Ras GTPases, participates in T-cell signaling responses. Mol Cell Biol 2007;27:8127-42. (Pubitemid 350234228) (Pubitemid 350234228)
41. Fernandez-Medarde A, Santos E. The RasGrf family of mammalian guanine nucleotide exchange factors. Biochim Biophys Acta 2011;1815: 170-88.
42. Lin WW, Hsieh SL. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol 2011;81:838-47.
43. Kawase T, Ohki R, Shibata T, Tsutsumi S, Kamimura N, Inazawa J, et al. PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell 2009;136:535-50.
44. Tommerup N, Vissing H. Isolation and fine mapping of 16 novel human zinc finger-encoding cDNAs identify putative candidate genes for developmental and malignant disorders. Genomics 1995;27:259-64.
45. Raldow A, Hamstra DA, Kim S, Yu JB. Salvage external beam radiotherapy for prostate cancer after radical prostatectomy: current status and controversy. Oncology (Williston Park) 2010;24:692-700, 2.
46. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, et al. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics 2010;5:499-508.
47. Schreiber J, Enderich J, Sock E, Schmidt C, Richter-Landsberg C, Wegner M. Redundancy of class III POU proteins in the oligodendrocyte lineage. J Biol Chem 1997;272:32286-93. (Pubitemid 28011908) (Pubitemid 28011908)
48. Rahmatpanah FB, Carstens S, Guo J, Sjahputera O, Taylor KH, Duff D, et al. Differential DNA methylation patterns of small B-cell lymphoma subclasses with different clinical behavior. Leukemia 2006;20: 1855-62. (Pubitemid 44574996) (Pubitemid 44574996)
49. Boumber Y, Issa JP. Epigenetics in cancer: what's the future? Oncology (Williston Park) 2011;25:220-6, 228.